-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ sp.
MONTREAL , May 20, 2022 /PRNewswire/ -- CellCarta, a leading global provider of precision medicine laboratory services, today announced the acquisition of the commercial rights to Precision Assays antibody panels and assa.
Precision Assays is a leader in next-generation targeted proteomic detection solutio.
Precision Assays, a spin-off from the Fred Hutchinson Cancer Research Center ("Fred Hutchinson Center"), develops and deploys high-end multiplex quantification for customers in the pharmaceutical and biotechnology industries Immuno-MRM mass spectrometry detecti.
CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq
The acquisition of Precision Assays, a large-scale targeted mass spectrometry assay characterized according to the National Cancer Institute Clinical Proteomics Tumor Analysis Consortium (CPTAC) Level 2 Guidelines, greatly expands CellCarta's capabilities in off-the-shelf multiplex protein quantitation products that can Direct use in immuno-oncology clinical and preclinical resear.
" Precision Assays ' extensive robust assays characterized according to CPTAC guidelines, along with mature proof-of-concept data, will enable CellCarta to confidently <.
Paulovich said: " CellCarta , a global contract research organization with expertise in targeted mass spectrometry and biomarker detection, will serve as an ideal partner to deploy and industrialize our platform to support discovery, translational and clinical research, Especially in the fields of precision medicine and immuno-oncolo.
CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq